Physician

M Yaser Haffar, MD

According to 2025 Medicare claims, M. Haffar, MD (NPI: 1275528515) practices cardiology in the Huntington-Ashland, WV-KY-OH market, with the plurality of this provider's patient population coming from Putnam, WV. This provider's primary affiliated billing organization is CARDIOVASCULAR CONSULTANTS PLLC (NPI: 1588658199; TIN: 550766617) and primary practice location at 25526-8707. Haffar is affiliated with the Vandalia Health Network (ACO ID: A4513), participating under the MSSP model.

Haffar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,822 traditional Medicare patients, billed 6,982 HCPCS/CPT codes, and received $354,836 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 9,668 prescription claims across 1,061 beneficiaries totaling $1,478,033 in drug costs, led by Eliquis (Apixaban). 2022 DME data shows 16 claims. Open Payments data shows 77 records totaling $1,370. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $602,737 to $354,836. In contrast, Part D prescription costs have moved sharply higher in recent years, from $579,409 to $1,478,033. For DME billing, this smaller-volume category moved sharply higher in recent years, from $14,524 to $36,331.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,115	11,209	$602,737
2016	2,436	12,243	$638,084
2017	2,702	11,558	$595,471
2018	2,937	12,183	$668,742
2019	2,823	11,527	$608,377
2020	2,797	11,406	$565,480
2021	2,762	10,801	$535,464
2022	2,322	9,050	$441,517
2023	2,105	7,644	$372,373
2024	1,822	6,982	$354,836

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	712	7,028	$579,409
2016	764	7,730	$628,107
2017	771	7,852	$659,646
2018	805	6,928	$736,691
2019	827	5,974	$915,439
2020	843	6,701	$961,038
2021	883	7,041	$1,051,410
2022	892	7,598	$1,230,895
2023	980	8,383	$1,442,060
2024	1,061	9,668	$1,478,033

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	26	$2,472
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	13	34	$71,524
2019	N/R	12	$25,574
2020	N/R	17	$38,398
2021	N/R	N/R	N/R
2022	N/R	16	$36,331
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	387	636	$84
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	562	602	$75
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	182	722	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	422	628	$13
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	1,151	1,611	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	896	39,322	$748,100
Xarelto	Rivaroxaban	310	16,238	$292,945
Entresto	Sacubitril/Valsartan	213	9,480	$207,068
Jardiance	Empagliflozin	57	2,370	$45,907
Farxiga	Dapagliflozin Propanediol	35	1,050	$19,839

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	77	$1,370	Kestra Medical Technology Services, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for M. Yaser Haffar, MD?

Tedicare shows public-source Medicare data for M. Yaser Haffar, MD (NPI 1275528515), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does M. Yaser Haffar, MD have ACO affiliation data?

M. Yaser Haffar, MD is shown with ACO affiliation data for Vandalia Health Network (MSSP, ACO ID A4513).

What billing organization is linked to M. Yaser Haffar, MD?

M. Yaser Haffar, MD is linked to CARDIOVASCULAR CONSULTANTS PLLC (billing NPI 1588658199) in the available physician profile data.

Does M. Yaser Haffar, MD have Open Payments data?

M. Yaser Haffar, MD has 77 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.